A randomized controlled trial from the May issue of Clinical Therapeutics provides the most detailed dataset to date on oral cannabis for three chronic pain conditions. Researchers from the University at Buffalo, the University of Michigan, and data provider MoreBetter treated 164 patients in California over twelve weeks with three different capsule formulations. The result: significant improvements in pain, sleep, and mental health across all indications. Cognitive function remained unaffected as the sole endpoint.
📑 Inhaltsverzeichnis
The Study at a Glance
The study is an RCT—a randomized controlled trial with three active comparison groups. 164 adult cannabis-experienced participants from California’s regulated market were randomized into one of three capsule conditions and monitored their symptoms over twelve weeks using app-based self-documentation. The indications were distributed across fibromyalgia with 64 participants, knee and hip osteoarthritis with 75, and rheumatoid arthritis with 25.
The three tested formulations differed clearly in their cannabinoid profile. Group one received a 1:1 capsule with 12.5 milligrams each of THC and CBD. Group two received a minor cannabinoid blend of 10 milligrams THCa, 10 milligrams CBDa, 5 milligrams CBG, and 3 milligrams CBC. Group three received a CBD-dominant variant without THC, consisting of 10 milligrams CBD and 10 milligrams CBDa. This three-way division allows for the first direct comparison between classical balanced therapy, newer minor cannabinoid profiles, and CBD monotherapy under real-world conditions.
What the Data Shows
The authors report significant improvements across all measured symptoms, with the exception of cognitive function. Effect sizes are described in the secondary report as „small to large,“ without the original study reporting indication-specific subgroup data in the freely accessible summary. Specifically, the researchers cite substantial progress in sleep quality, mental health, and overall quality of life. Pain was measured using standard scales, supplemented by measures of physical function and mental burden.
The cognitive finding is clinically noteworthy. THC-containing therapies are often prescribed in clinical practice with concerns about concentration loss. The study data show no measurable disadvantage for oral administration at the tested dosage, but also no improvement. This supports the picture from the in-house JAMA study of older cannabis users, in which older adults describe cannabis primarily as a replacement for sleep and pain medications, not as an additional risk.
Three Indications, Three Scenarios
The fibromyalgia group is the largest with 64 participants. It represents a disease condition considered particularly underserved in Germany. Standard analgesics have limited efficacy, and antidepressants and anticonvulsants carry relevant side effect profiles. Our in-house research on cannabis and rheumatic complaints has described for years why this patient group is pushing for cannabis options. The new RCT data now provide controlled evidence that patients‘ subjective experience in the pain and sleep domains is reproducible.
The osteoarthritis group with 75 participants addresses a widespread disease. Millions in Germany suffer from degenerative joint pain, classically treated with NSAIDs, opioids, and intra-articular injections. The Buffalo data show that oral cannabinoid capsules also improve pain and function here, without sedation appearing as a blocking effect in self-documentation. For the German healthcare landscape, this is relevant insofar as BfArM import figures signal a growing stream of patients whose indications lie beyond classical oncology and spasticity.
The smallest subgroup with 25 participants represents rheumatoid arthritis. It is the methodological weakness of the study and simultaneously the most intriguing touchpoint with current cannabinoid research. Just days ago, we reported on an Israeli CBG study showing 98 percent IL-6 reduction, which provides a mechanistic explanation for the anti-inflammatory effects of minor cannabinoids. The Buffalo formulation contains precisely this CBG plus CBC in the second study group.
Where the Study Reaches Its Limits
Three methodological limitations deserve attention. First, the small RA sample of 25, which complicates statistically reliable subgroup conclusions. Second, the geographic restriction to California, a market with established regulated provision and high cannabis prevalence in the general population. Third, the selection criterion of cannabis experience. All participants were already users; tolerance and expectation effects are not controlled.
For translation into German healthcare practice, this means: the effects are real, the magnitude is plausible, but applicability to cannabis-naive patients in pharmacies must be studied separately. The ongoing online survey by the University Medicine Mainz on everyday use of medical cannabis should provide complementary real-world data in a few months that closes precisely the gap the Buffalo study necessarily leaves.
Implications for Patient Care and Reimbursement Debate
The temporal coincidence is remarkable. While Berlin is discussing the removal of cannabis flower reimbursement in statutory health insurance, an RCT demonstrates efficacy for three of the most common pain indications. The argument from payers that evidence is lacking comes under further pressure. Medical guideline commissions will review the data in the second half of the year, and the already ongoing discussion about realistic dosing schemes gains new empirical footing. Those following prescribing patterns between high-THC flowers and lower standard doses see in the Buffalo study an argument for moderate, balanced cannabinoid profiles rather than maximal THC concentrations.
Frequently Asked Questions
Which cannabis formulation performed best in the study?
The freely accessible study report does not break down effect sizes by indication and group. All three formulations—the balanced THC-CBD capsule, the minor cannabinoid blend with CBG and CBC, and the CBD-dominant variant—showed significant improvements in pain, sleep, and mental health. A direct comparison of subgroups requires the full original text in Clinical Therapeutics.
Are the data transferable to German patients?
Partly. The mechanisms of action are universal and effect sizes are plausible. However, all participants were cannabis-experienced from California’s regulated market. For cannabis-naive patients in German pharmacies, dosing and titration must be medically supervised. Real-world care studies from the German market remain lacking; the Mainz survey should partially fill this gap.
Why didn’t cognitive function improve?
The study tested three oral formulations at moderate doses over twelve weeks. Cognitive function neither improved nor deteriorated measurably. This is clinically relevant because it relativizes the widespread objection to THC-containing pain therapy. Cognitive impairment in the acute phase after inhalation of high THC doses is well documented, but it does not translate into chronic functional impairment with oral daily medication at the tested dosage.
What role do minor cannabinoids like CBG and CBC play?
The second study group contained a blend of THCa, CBDa, CBG, and CBC. These compounds are increasingly discussed in research as anti-inflammatory and potentially pain-modulating agents. Current studies such as the Israeli work on CBG in rheumatoid arthritis and research on the antimicrobial effects of CBC with silver against hospital pathogens show that minor cannabinoids have their own therapeutic profiles beyond the entourage effect.
Where can I find the original study?
The study was published in Clinical Therapeutics in May 2026. The DOI reference and abstract are accessible at clinicaltherapeutics.com; the full text is behind a paywall. Lead researchers are from the University at Buffalo, the University of Michigan Medical School, and the observation platform MoreBetter.
Hast du Erfahrung mit Cannabis bei chronischen Schmerzen?
Sources: Study in Clinical Therapeutics, May 2026 (University at Buffalo, University of Michigan Medical School, MoreBetter); reporting from Marijuana Moment of May 26, 2026; supplementary research on German care trends based on BfArM import figures.
Branchen-Update
News, Analysen und Reportagen — mehrmals im Monat direkt in dein Postfach.
Folge uns
